Results 91 to 100 of about 155 (115)
Some of the next articles are maybe not open access.
Esketamine nasal spray offers rapid improvement in treatment‐resistant depression
The Brown University Psychopharmacology Update, 2019Esketamine nasal spray in combination with a newly initiated antidepressant was more effective than a new antidepressant plus placebo in reducing depressive symptoms in patients with treatment‐resistant depression, a Phase 3 study has found. Esketamine, the S‐enantiomer of ketamine, recently received Food and Drug Administration (FDA) approval for ...
openaire +1 more source
Analysis of trial confirms efficacy of esketamine nasal spray in TRD
The Brown University Psychopharmacology UpdateSeveral sensitivity analyses of a Phase 3b trial have demonstrated that esketamine nasal spray was consistently more efficacious than extended‐release quetiapine in patients with treatment‐resistant depression (TRD). The additional analyses of the ESCAPE‐TRD trial used multiple thresholds for remission and relapse.
openaire +1 more source
Esketamine Nasal Spray in Major Depressive Disorder: A Meta‐Analysis of Randomized Controlled Trials
Clinical Pharmacology & TherapeuticsDespite being approved by the US FDA and the EU European Medicines Agency, the performance of esketamine nasal spray as an adjunctive therapy with an antidepressant in major depressive disorder is still controversial. Comprehensive retrieval in Embase, Pubmed, and Web of Science was conducted to identify randomized controlled trials comparing ...
Zhibin Wang +6 more
openaire +2 more sources
Cost Efficiency of Esketamine Nasal Spray Versus Quetiapine for Treatment Resistant Depression
CNS SpectrumsObjectiveTo compare the per-patient direct and indirect costs associated with achieving remission with esketamine nasal spray plus oral antidepressants (ESK NS+OAD) versus quetiapine extended release plus oral antidepressants (QTP XR+OAD) among patients with treatment-resistant depression (TRD).
Kristin Clemens +9 more
openaire +1 more source
Post‐approval analysis finds favorable safety for esketamine nasal spray
The Brown University Psychopharmacology UpdateNearly five years of post‐approval safety data for esketamine nasal spray have uncovered no new safety concerns associated with the formulation, an analysis has found. Most adverse events occurred during the first treatment session, with incidence decreasing over the course of treatment. Results were published online Sept. 10, 2025,
openaire +1 more source
Esketamine nasal spray not recommended by NICE
PharmacoEconomics & Outcomes News, 2020openaire +1 more source
Esketamine nasal spray shows rapid effects in suicidal patients
The Brown University Psychopharmacology Update, 2021openaire +1 more source
Safety results favorable for esketamine nasal spray for depression
The Brown University Psychopharmacology Update, 2020openaire +1 more source